Revolutionary blueprint aims to enhance nurse’s impact on patient outcomes

Plus, news about Nicox, Soleus and Mol­e­c­u­lar Tem­plates: Ake­so Bio­phar­ma’s $250M place­ment: The Hong Kong-based com­pa­ny, which is de­vel­op­ing a close­ly watched bis­pe­cif­ic an­ti­body with

Shorter high-dose rifampicin regimens proved safe for treating pulmonary tuberculosis (TB), but failed to demonstrate noninferiority compared with the standard 6-month regimen, a phase III

The FDA’s Car­dio­vas­cu­lar and Re­nal Drugs Ad­vi­so­ry Com­mit­tee will meet to­mor­row to dis­cuss the ef­fi­ca­cy of Al­ny­lam’s On­pat­tro (patisir­an) for the treat­ment of car­diomy­opa­thy of